Remarkable Response to Dabrafenib and Trametinib in a V-Raf Murine Sarcoma Viral Oncogene Homolog B (BRAF) V600E-Mutated Lung Adenocarcinoma Patient With Poor Performance Status and Respiratory Failure: A Case Report
Satoshi Anai, Kohei Isa, Rin Chibana, Shiho Ueno, Yoko Sato · 2024
Read Remarkable Response to Dabrafenib and Trametinib in a V-Raf Murine Sarcoma Viral Oncogene Homolog B (BRAF) V600E-Mutated Lung Adenocarcinoma Patient With Poor Performance Status and Respiratory Failure: A Case Report by Satoshi Anai, Kohei Isa, Rin Chibana, Shiho Ueno, Yoko Sato (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11700529.txt.
Description
Satoshi Anai and co-authors report the case of a 73-year-old man with lung cancer who responded strikingly to a two-drug targeted therapy. Their report appeared in 2024. The man arrived with worsening breathlessness and breathing failure. Scans showed widespread shadowing in his right lung. A biopsy confirmed lung adenocarcinoma carrying a gene change called BRAF V600E. He was weak and needed oxygen to keep his blood levels safe.
After careful discussion and consent, the team started the drug pair dabrafenib and trametinib despite the risks. His breathing and scans improved markedly. He stayed on the treatment with no major side effects, and the disease remained stable. The authors present the case as early evidence that targeted drugs can help even frail patients when the gene match is right.
Catalog record
| CREATOR | Satoshi Anai, Kohei Isa, Rin Chibana, Shiho Ueno, Yoko Sato |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 13 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |